With the recent FDA approvals of the first CAR-T therapies, the floodgates for cellular immunotherapies seem to be opening. In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of these therapies in more detail.
Floodgates
With the FDA approving first Kymriah and now Yescarta, the floodgates for cellular immunotherapies seem to be opening, with a lot more approvals expected in the coming years. Understanding the intellectual property (IP) ramifications within this rising tide is vital, not least as the field becomes increasingly crowded and competitive.